These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22291084)

  • 1. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
    Jakubowiak AJ; Benson DM; Bensinger W; Siegel DS; Zimmerman TM; Mohrbacher A; Richardson PG; Afar DE; Singhal AK; Anderson KC
    J Clin Oncol; 2012 Jun; 30(16):1960-5. PubMed ID: 22291084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
    J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
    Richardson PG; Weller E; Jagannath S; Avigan DE; Alsina M; Schlossman RL; Mazumder A; Munshi NC; Ghobrial IM; Doss D; Warren DL; Lunde LE; McKenney M; Delaney C; Mitsiades CS; Hideshima T; Dalton W; Knight R; Esseltine DL; Anderson KC
    J Clin Oncol; 2009 Dec; 27(34):5713-9. PubMed ID: 19786667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
    Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
    Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
    Richardson PG; Siegel D; Baz R; Kelley SL; Munshi NC; Laubach J; Sullivan D; Alsina M; Schlossman R; Ghobrial IM; Doss D; Loughney N; McBride L; Bilotti E; Anand P; Nardelli L; Wear S; Larkins G; Chen M; Zaki MH; Jacques C; Anderson KC
    Blood; 2013 Mar; 121(11):1961-7. PubMed ID: 23243282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Berenson JR; Yellin O; Patel R; Duvivier H; Nassir Y; Mapes R; Abaya CD; Swift RA
    Clin Cancer Res; 2009 Feb; 15(3):1069-75. PubMed ID: 19188182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
    Badros A; Burger AM; Philip S; Niesvizky R; Kolla SS; Goloubeva O; Harris C; Zwiebel J; Wright JJ; Espinoza-Delgado I; Baer MR; Holleran JL; Egorin MJ; Grant S
    Clin Cancer Res; 2009 Aug; 15(16):5250-7. PubMed ID: 19671864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
    White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
    Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
    van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
    Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
    Ghobrial IM; Munshi NC; Harris BN; Shi P; Porter NM; Schlossman RL; Laubach JP; Anderson KC; Desaiah D; Myrand SP; Wooldridge JE; Richardson PG; Abonour R
    Am J Hematol; 2011 Jul; 86(7):573-8. PubMed ID: 21630305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
    Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
    J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Berenson JR; Matous J; Swift RA; Mapes R; Morrison B; Yeh HS
    Clin Cancer Res; 2007 Mar; 13(6):1762-8. PubMed ID: 17363530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
    Lonial S; Vij R; Harousseau JL; Facon T; Moreau P; Mazumder A; Kaufman JL; Leleu X; Tsao LC; Westland C; Singhal AK; Jagannath S
    J Clin Oncol; 2012 Jun; 30(16):1953-9. PubMed ID: 22547589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
    Richardson PG; Chanan-Khan AA; Lonial S; Krishnan AY; Carroll MP; Alsina M; Albitar M; Berman D; Messina M; Anderson KC
    Br J Haematol; 2011 Jun; 153(6):729-40. PubMed ID: 21534941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
    Popat R; Oakervee H; Williams C; Cook M; Craddock C; Basu S; Singer C; Harding S; Foot N; Hallam S; Odeh L; Joel S; Cavenagh J
    Br J Haematol; 2009 Mar; 144(6):887-94. PubMed ID: 19183191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yellin O; Bessudo A; Boccia RV; Noga SJ; Gravenor DS; Patel-Donnelly D; Siegel RS; Kewalramani T; Gorak EJ; Nassir Y; Swift RA; Mayo D
    Br J Haematol; 2013 Feb; 160(3):321-30. PubMed ID: 23150919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.